PRESS RELEASE May 20, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it hosted a virtual R&D day event, during which
Investegate |Saniona AB Announcements | Saniona AB: Saniona Hosts Research and Development (R&D) Day on Proprietary Ion Channel Drug Discovery Engine and Pipeline Programs investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Saniona Launches New Video Series to Highlight the Impact of Prader-Willi Syndrome and .
Saniona ABMay 10, 2021 GMT
PRESS RELEASE
May 10, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced its “Saniona’s Community Voices” video series, which will feature the voices of people living with rare diseases, their caregivers and their medical professionals. The series will launch during the month of May, which is both Prader-Willi syndrome (PWS) and Brain Tumor Awareness Month and will begin by spotlighting the impact of these conditions on patients and their families.
Saniona AB: Saniona publishes its year-end report for 2020
Revenue was SEK 8.2 M (7.2 M)
Operating loss was SEK -159.4 (-93.6 M)
Net loss was SEK -73.4 M (-68.8 M)
Earnings per share were SEK -1.79 (-2.67)
Diluted earnings per share were SEK -1.75 (-2.67)
Q4 2020 (Q4 2019 restated)
Revenue was SEK 1.6 M (0.0 M)
Operating loss was SEK -68.8 M (-28.2 M)
Net loss was SEK -45.6 M (-6.8 M)
Earnings per share were SEK -0.73 (-0.24)
Diluted earnings per share were SEK -0.73 (-0.24)
Business highlights in Q4 2020
Saniona achieved
positive top-line Phase 2 results from the open-label extension study of Tesomet in patients with HO. Patients treated with Tesomet for nearly one year (24 weeks in a double-blind trial followed by a 24-week open label extension) demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference, as well as improvements in glycemic control. Tesomet was well tolerated, and no clinically meaningful differe